Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 6/20 | 0.43 |
| ▸ | CSF1R | P07333 | 5/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.41 |
| ▸ | PYGL | P06737 | 2/20 | 0.41 |
| ▸ | PYGM | P11217 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21425527 | 1.00 | TGFBR1 (0.43) | TGFBR1CSF1RPDGFRAPDGFRBPYGL | |
| SCHEMBL21408144 | 0.87 | KDM4E (0.42) | TGFBR1CSF1RPDGFRAPDGFRBPYGL | |
| SCHEMBL21425528 | 0.87 | TGFBR1 (0.53) | TGFBR1CSF1RPDGFRAPDGFRBPYGL | |
| SCHEMBL21425592 | 0.86 | KDR (0.50) | CSF1R | |
| SCHEMBL21425598 | 0.86 | TGFBR1 (0.39) | TGFBR1CSF1RPDGFRAPDGFRBPYGL | |
| SCHEMBL31740748 | 0.77 | TGFBR1 (0.43) | TGFBR1CSF1RPDGFRAPDGFRB | |
| SCHEMBL16028837 | 0.76 | TGFBR1 (0.43) | TGFBR1CSF1RPDGFRAPDGFRB | |
| SCHEMBL30891513 | 0.76 | TGFBR1 (0.43) | TGFBR1CSF1RPDGFRAPDGFRB | |
| SCHEMBL19224629 | 0.74 | RIPK1 (0.49) | PDGFRAPYGLPYGMP2RX3 | |
| SCHEMBL6014711 | 0.74 | KDR (0.49) | PDGFRAALDH1A1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3632907-B1 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2024-02-28 | — | — | EP | disclosed |